Mycosis Fungoides Clinical Trials

27 recruitingLast updated: June 18, 2026

There are 27 actively recruiting mycosis fungoides clinical trials across 12 countries. Studies span Phase 2, Phase 1, Early Phase 1, Phase 3. Top locations include Houston, Texas, United States, New York, New York, United States, Duarte, California, United States. Updated daily from ClinicalTrials.gov.


Mycosis Fungoides Trials at a Glance

27 actively recruiting trials for mycosis fungoides are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Houston, New York, and Duarte. Lead sponsors running mycosis fungoides studies include City of Hope Medical Center, M.D. Anderson Cancer Center, and Mayo Clinic.

Browse mycosis fungoides trials by phase

Treatments under study

About Mycosis Fungoides Clinical Trials

Looking for clinical trials for Mycosis Fungoides? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Mycosis Fungoides trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Mycosis Fungoides clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 1Phase 2

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Recurrent Mycosis FungoidesRefractory Mycosis FungoidesSezary Syndrome+5 more
City of Hope Medical Center78 enrolled4 locationsNCT03011814
Recruiting
Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting

A Registry for People With T-cell Lymphoma

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+27 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141
Recruiting
Early Phase 1

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

Mycosis Fungoides
Northwestern University25 enrolled1 locationNCT05838599
Recruiting
Phase 2

Photopheresis in Early-stage Mycosis Fungoides

Mycosis FungoidesCutaneous T Cell Lymphoma
Columbia University74 enrolled1 locationNCT05680558
Recruiting
Phase 2

Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides

Mycosis FungoidesLocalized Skin Lesion
M.D. Anderson Cancer Center50 enrolled1 locationNCT03398161
Recruiting
Phase 1

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Mycosis FungoidesCutaneous T Cell Lymphoma
University of Alabama at Birmingham10 enrolled1 locationNCT05414500
Recruiting
Phase 2

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Mycosis FungoidesLymphomatoid PapulosisSezary Syndrome
Memorial Sloan Kettering Cancer Center58 enrolled8 locationsNCT03587844
Recruiting
Phase 3

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Mycosis FungoidesCutaneous T Cell LymphomaCTCL+1 more
Soligenix80 enrolled17 locationsNCT06470451
Recruiting

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

Mycosis FungoidesLymphomatoid Papulosis
M.D. Anderson Cancer Center100 enrolled1 locationNCT06207812
Recruiting
Phase 2

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Mycosis Fungoides
M.D. Anderson Cancer Center30 enrolled1 locationNCT05357794
Recruiting

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

Atopic DermatitisEczemaMycosis Fungoides+2 more
University of Pittsburgh200 enrolled1 locationNCT00177268
Recruiting

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Cutaneous T Cell LymphomaCutaneous T-Cell Lymphoma/Mycosis FungoidesCutaneous T-Cell Lymphoma/Sezary Syndrome
Fondazione Italiana Linfomi - ETS400 enrolled18 locationsNCT06588868
Recruiting
Phase 2

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Lymphoma, T-CellT-LGL LeukemiaNK-LGL Leukemia+7 more
Institute of Hematology & Blood Diseases Hospital, China48 enrolled2 locationsNCT06716658
Recruiting

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Non-Hodgkin's LymphomaMycosis Fungoides
Stanford University2,000 enrolled13 locationsNCT02848274
Recruiting
Phase 2

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage IB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8+5 more
City of Hope Medical Center34 enrolled3 locationsNCT04930653
Recruiting

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

Mycosis FungoidesSezary Syndrome
Kyowa Kirin Co., Ltd.15 enrolled6 locationsNCT07132567
Recruiting
Phase 1

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

T-cell LymphomaPeripheral T Cell LymphomaMycosis Fungoides+8 more
SciTech Development, Inc.46 enrolled10 locationsNCT04234048